Comparing Alternative Strategies for Pharmacologic Management of Attention-Deficit / Hyperactivity Disorder in Children and Adolescents

Page last updated April 14, 2026

Study Design: Intervention Trial
Principal Investigator: Stephen Faraone
Institution: The Research Foundation For The State University of New York
Funder: Patient-Centered Outcomes Research Institute (PCORI); (Project webpage)
Participating PCORnet® Clinical Research Networks: GPC, INSIGHT, PEDSnet
Therapeutic Area: Mental and Behavioral Health
Status: Not yet recruiting

Research Question(s):

Are non-stimulants equally appropriate first line medications as stimulants for treating ADHD in school age youth, and which youth are most likely to benefit from which approach? This question addresses a health care challenge relevant to all youth with ADHD, their prescribers, and their parents.

Comparative Effectiveness of Available Treatments for Sinus and Ear Infections in Children: Which Children Benefit from Which Treatment? (MEASURE Trial)

Page last updated March 12, 2026

Study Design: Intervention Trial
PCORnet Infrastructure: Single IRB, Patient partners or engagement, Clinical Research Collaboration Agreement
Principal Investigator: Nader Shaikh
Institution: University of Pittsburgh
PCORnet® Network Partner: PaTH
Funder: Patient-Centered Outcomes Research Institute (PCORI); (Project webpage)
Funding Date: 2025
Study Duration: 2026 – 2032
Therapeutic Area: Infectious Disease
Status: Unknown Status

Research Question(s): Which children benefit from which treatment for sinus and ear infections?

Teaming Researchers Up with Stakeholders to Test Trustworthy Engagement and Measure: TRUST TEAM

Page last updated April 14, 2026

ClinicalTrials.gov#NCT07358559
Study Design: Other
PCORnet Infrastructure: Single IRB, Patient partners or engagement
Principal Investigator: Virginia A. Brown
Institution: The Hastings Center for Bioethics
Funder: Patient-Centered Outcomes Research Institute (PCORI); (Project webpage)
Funding Date: 2024
Study Duration: 2025 - 2028
Therapeutic Area: Engagement Methods
Status: Unknown Status

Research Question(s): Do individuals' beliefs about the trustworthiness of a university and other research organizations (e.g., academic medical centers) correlate to how much they trust researchers they partner with on research projects?

Comparing Two Durations of Antibiotic Treatment for Children Hospitalized with Common Infections

Page last updated March 12, 2026

Study Design: Intervention Trial
PCORnet Infrastructure: Single IRB, Patient partners or engagement
Principal Investigator: Sunitha Kaiser and Katherine Auger
Institution: University of California, San Francisco
PCORnet® Network Partner: REACHnet
Funder: Patient-Centered Outcomes Research Institute (PCORI); (Project webpage)
Funding Date: 2025
Study Duration: 2025 – 2032
Participating PCORnet® Clinical Research Networks: GPC, OneFlorida+, PaTH, PEDSnet, REACHnet, STAR
Therapeutic Area: Infectious Disease
Status: Enrolling by invitation

Research Question(s):
For children hospitalized with pneumonia, skin infections, or urinary infections, do they recover better and have fewer side effects with a 5-day course of antibiotics, or a 10-day course of antibiotics?

A Randomized Controlled Trial Comparing Renal Effects of Vancomycin Combined With Either Piperacillin/tazobactam or Meropenem

Page last updated February 4, 2026

Study Design: Intervention Trial
PCORnet Infrastructure: Single IRB, Patient partners or engagement, Clinical Research Collaboration Agreement
Principal Investigator: Daniel Freilich
Institution: Other
Funder: Patient-Centered Outcomes Research Institute (PCORI); (Project webpage)
Funding Date: 2025
Study Duration: 2026 – 2029
Participating PCORnet® Clinical Research Networks:
ADVANCE, GPC, INSIGHT, OneFlorida+, PaTH, REACHnet, STAR
Therapeutic Area
: Infectious Disease; Nephrology
Status: Not yet recruiting

Research Question(s): 1) In hospitalized patients with severe infections, does the antibiotic combination workhorse, vancomycin and piperacillin/tazobactam (VPT), cause more kidney injury than another standard antibiotic combination, vancomycin and meropenem (VM), and 2) what is VPT's relative impact on other patient centric outcomes such as mortality, other kidney effects, hospital length of stay, readmissions, complications, and quality of life.

The Dose Trial: Dose Intensity of Behavioral Interventions for Childhood Obesity

Page last updated February 4, 2026

ClinicalTrials.gov#: NCT06654323
Study Design: 
Intervention Trial
PCORnet Infrastructure: Common Data Model (CDM), Single IRB, Patient partners or engagement
Principal Investigator: Dr. Bill Heerman
Institution: Vanderbilt University Medical Center
PCORnet® Network Partner: STAR
Funder: Patient-Centered Outcomes Research Institute (PCORI); (Project webpage)
Funding Date: 2024
Study Duration: 2024 – 2030
Participating PCORnet® Clinical Research Networks:
STAR
Therapeutic Area: Metabolic Disorders; Other, Pediatric Obesity
Status: Recruiting

Research Question(s):

Can children with obesity achieve meaningful improvements in their health with fewer hours of treatment than currently recommended? This study is testing whether shorter versions of a family-based lifestyle program, delivered through pediatric clinics, are just as effective as the full 26-hour version currently recommended by national guidelines. The goal is to find out if families can benefit from a lower-dose program that is easier to complete, while still helping children improve their weight, quality of life, and health behaviors.

Clinical Outcomes of Medications Post Anti-TNF: Researching Effectiveness in Pediatric IBD

Page last updated November 12, 2025

Study Design: Prospective Observational Study
PCORnet Infrastructure: Common Data Model (CDM), Single IRB, Patient partners or engagement, Clinical Research Collaboration Agreement
Principal Investigator: Michael D. Kappelman
Institution: University of North Carolina at Chapel Hill
PCORnet® Network Partner: STAR
Funder: Patient-Centered Outcomes Research Institute (PCORI); (Project webpage)
Funding Date: 2025
Study Duration: 2025 – 2031
Participating PCORnet® Clinical Research Networks: GPC, INSIGHT, OneFlorida+, PaTH, PEDSnet, REACHnet, STAR
Therapeutic Area: Gastroenterology
Status: Not yet recruiting

Research Question(s):

  1. Can we determine which medicine is the safest and most effective at treating kids with Crohn's disease or ulcerative colitis when the first medicine they take does not work for them?

A Comparative Effectiveness Study of Oral Medications Used for Migraine Prevention: The SPT Comparison Study

Page last updated October 29, 2025

Study Design: Intervention Trial
PCORnet Infrastructure: Single IRB, Patient partners or engagement
Principal Investigator: Todd Schwedt
Institution: Mayo Clinic
PCORnet® Network Partner: STAR
Funder: Patient-Centered Outcomes Research Institute (PCORI); (Project webpage)
Funding Date: 2024
Study Duration: 2025 – 2029
Participating PCORnet® Clinical Research Networks: GPC, One Florida+, PaTH, STAR
Therapeutic Area: Neurology
Status: Recruiting

Research Question(s):

Is a newer oral migraine preventive medication (atogepant) more effective for treating migraines than two older medications (propranolol, topiramate), each of which is commonly used in clinical practice and has strong levels of evidence supporting their efficacy?

Tube Size Randomized Trial during Emergency Tracheal Intubation

Page last updated November 07, 2025

Study Design: Intervention Trial
PCORnet Infrastructure: Single IRB, Patient partners or engagement, Clinical Research
Collaboration Agreement
Principal Investigator: Jonathan Casey
Institution: Vanderbilt University Medical Center
PCORnet® Network Partner: STAR
Funder: Patient-Centered Outcomes Research Institute (PCORI); (Project webpage)
Funding Date: 2024
Study Duration: 2025 – 2029
Participating PCORnet® Clinical Research Networks: ADVANCE, OneFlorida+, STAR
Therapeutic Area: Pulmonology
Status: Enrolling by invitation

Research Question(s):

  1. Do smaller breathing tubes prevent long-term problems with breathing, speaking and swallowing?
  2. Are smaller breathing tubes as good as larger breathing tubes for getting patients through their illness and off the breathing machine?

Comparative Effectiveness of Carvedilol versus Metoprolol Succinate in Heart Failure Patients with an Implantable Cardioverter Defibrillator

Page last updated August 22, 2025

ClinicalTrials.gov#: NCT06964464
Study Design:
Intervention Trial
PCORnet Infrastructure: Common Data Model (CDM), Single IRB, Patient partners or engagement
Principal Investigator: Mehmet Aktas
Institution: University of Rochester
PCORnet® Network Partner: External
Funder: Patient-Centered Outcomes Research Institute (PCORI); (Project webpage)
Funding Date: 2024
Study Duration: 2025 – 2031
Participating PCORnet® Clinical Research Networks: GPC, INSIGHT, PaTH, REACHnet
Therapeutic Area: Cardiovascular
Status: Recruiting

Research Question(s):
In this study, we are comparing two commonly used beta-blockers-carvedilol and metoprolol succinate-in people who have heart failure and an implanted defibrillator. We want to find out if carvedilol is more effective than metoprolol succinate at preventing dangerous heart rhythm problems, hospitalizations for heart issues, and deaths caused by heart disease.